Advanced Biomedical Research
The frequency of agitation due to inappropriate use of naltrexone in addicts
Authors
Department of Clinical Toxicology, Isfahan Clinical Toxicology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: There is a high tendency among specialists to treat the addicts with naltrexone; withdrawal symptoms are frequent after taking naltrexone along with opioids. This study investigated the frequency of agitation due to inappropriate use of naltrexone in addicts.
Materials and Methods: This was a cross-sectional study, conducted in Noor and Aliasghar hospitals in Isfahan city. The study population included the addicts who were agitated as a result of naltrexone abuse. Scores of patients with agitation were measured with Richmond Agitation Sedation Scale (RASS). Patient outcomes including recovery without complications, recovery with complications (rhabdomyolysis), and mortality were recorded.
Results: All the patients with agitation caused by naltrexone abuse during 1 year were 40 people, of whom nine were excluded due to their comorbid diseases (diabetes or cardiovascular disease). Among the remaining 31 patients, 30 were male. The patients' mean age was 29.93 (5.24) years. The most common symptoms observed besides agitation was midriasis (41.9%), and vomiting (41.9%), A 38.8% of the patients scored 3 or 4, and, 61.2% scored 1 or 2 for agitation. The mean time for patients' restlessness scores to reach zero was 9.30 (3.71) h (min: 3 h, max: 18 h). All the patients in both groups were discharged with recovery without complication.
Conclusion: Considering the high prevalence of agitation in the poisoning emergency department due to inappropriate use of naltrexone, more accurate planning for administration of naltrexone in addicts seems necessary.
Keywords
| 1. |
Ferrari A, Bertolotti M, Dell'Utri A, Avico U, Sternieri E. Serum course of naltrexone and 6 beta-naltrexone levels during long-term treatment in drug addicts. Drug Alcohol Depend 1998;52:211-20.  |
| 2. |
Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003;12:3-11. |
| 3. |
Kleber HD. Pharmacologic treatments for opioid dependence: Detoxification and maintenance options. Dialogues Clin Neurosci 2007;9:455-70. |
| 4. |
Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 2006;31:319-28. |
| 5. |
O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279:229-34. |
| 6. |
Boyce SH, Armstrong PAR, Stevenson J. Effect of inappropriate naltrexone use in a heroin misuser. Emerg Med J 2003;20:381-2. |
| 7. |
Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction: A clinical perspective. Eur J Clin Pharmacol 2010;66:537-45. |
| 8. |
Mannelli P, De Risio S, Pozzi G, Janiri L, De Giacomo M. Serendipitous rapid detoxification from opiates: The importance of time-dependent processes. Addiction 1999;94:589-91. |
| 9. |
De Giacomo M, Gaspari R, Stefanelli A, Barelli A, Mannelli P. Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. Eur J Emerg Med 1999;6:153-5. |
| 10. |
Bristow K, Meek M, Clark N. Acute opioid withdrawal in the emergency department: Inadvertent naltrexone abuse. Emerg Med 2001;13:359-63. |
| 11. |
Quigley MA, Boyce SH. Unintentional rapid opioid detoxification. Emerg Med J 2001;18:494-5. |
| 12. |
Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41. |
| 13. |
Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002;166:1338-44. |
| 14. |
Pinelli A, Cighetti G, Trivulzio S. Plasma malondialdehyde levels and opiate withdrawal signs observed in rats treated with morphine plus naloxone: Effects of alpha-lipoic acid administration. Fundam Clin Pharmacol 2008;22:439-45. |
| 15. |
Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature. J Opioid Manag 2010;6:300-3.
|
)